Veeva Systems

Small biopharmas can now benefit from owning their safety system and data with an accelerated implementation! Join us for a 20-minute live demo to learn how! #pharma #pharmacovigilance #drugsafety 

Important news: Not all channels of scientific activity are created equal! The latest Pulse report findings prove this. The report quantifies the impact of different pre-launch scientific activities on treatment adoption and found that.. .. investment in medical congresses had the strongest influence. Read the Veeva Pulse Field Trends Report for insights that can help medical teams make more impactful investments before launch: https://bit.ly/3yar0qM #veevapulse #medicalaffairs #pharma #medicalscienceliaison

Ever wondered about the impact of non-promotional scientific activities on treatment adoption? Curious which of the congresses, publications, guidelines, clinical trials, or social media activity is the biggest driver? Answers to these and more in the new Veeva Pulse Field Trends Report: https://bit.ly/4bWrEpt

In the #manufacturing lab, bringing together test execution and sample management, improving right-first-time, and allowing review by exception can deliver access to key lab data faster. Veeva’s Jason Boyd explains how and why in Pharmaceutical Technology. https://lnkd.in/gRm4gX4S #qualitycontrol #qualityassurance

“Every interaction has to matter, and it should build off the previous one.” That was the key takeaway from a recent conversation between Veeva’s Chris Moore and pharmaphorum's Nicole Raleigh, as they discussed Veeva’s latest Pulse findings on declining HCP access. Chris explains why “targeting is everything” when it comes to building and maintaining trust between pharma field reps and HCPs. Watch the video here: https://lnkd.in/eudy64u7 #HCPengagement #lifesciences #pharmaceuticals Nicole R.

Companies can accelerate regulatory transformation by focusing on data, processes, and organizational models. Paul Attridge outlines how to establish a baseline for continuous transformation and more seamless #IDMP adoption in Bio-IT World. https://lnkd.in/e5J6xaMX #regulatoryoperations #lifesciences

“In the absence of data, we make up stories!” Wouldn’t it be great if we had concrete evidence on which non-promotional scientific activity has the strongest influence on treatment adoption? Stay tuned for the answer (to this question and more) in the new Veeva Pulse Field Trends Report, coming next week. #medicalaffairs #veevapulse #pharma

We're about one week away from our next Veeva Systems Pulse Field Trends Report! Just like last year, this summer's report will be our Medical Issue. With increasingly complex treatments in the pipeline, Medical Affairs plays a critical role in communicating scientific evidence. The report will highlight the impact of non-promotional scientific activities on treatment adoption at launch. We'll also quantify which of the congresses, publications, guidelines, clinical trials, or social media activity is the biggest driver. More to come on this, so keep an eye out! If you missed our last report, take a look to learn how biopharmas are addressing the trend of declining HCP access (and be sure to subscribe so you don't miss any future insights): https://bit.ly/3ye8cqt #medicalaffairs #veevapulse #pharmaceuticals

More than ever, HCPs and KOLs are looking to medical teams to be their partners in achieving the best patient outcome - providing current information to support treatment decisions, patient discussions, and peer-to-peer knowledge sharing. Learn more from Dr. Christoph Bug, MD, PhD, MBA about how measuring medical impact can help advance patient outcomes in this issue of MSL Journal. https://lnkd.in/eVv-etW7 #medicalaffairs #lifesciences

Veeva was the only company in Boston Business Journal's top 5 Largest Healthtech Companies in Massachusetts to grow last year. Read to find out why: https://bizj.us/1qln18 We are a growing #WorkAnywhere company #hiring in the Boston area. Check out the open positions: https://bit.ly/43Tg2kX